• Dr. Limdi is a clinical pharmacist and epidemiologist with significant expertise in pharmacogenomics and pharmacoepidemiology, from research and discovery to its application and implementation in clinical practice. Her research portfolio encompasses studies with both observational and a clinical trial designs and is focused on understanding the multiple factors that influence drug efficacy and safety, specifically anticoagulant and antiplatelet response. An established investigator in the field of pharmacogenomics, she has made significant contributions towards understanding of genetic basis of warfarin response. Her work has included discovering novel polymorphisms in CYP2C9, statistical analytic approaches that has ranged from candidate gene, haplotype based approach to genome-wide association and exome approaches, and a research portfolio that includes both prospective cohort and randomized clinical trials.

    Through her work, Dr. Limdi has collaborated extensively with pharmacogenomics researchers including with the International Warfarin Pharmacogenomics Consortium (IWPC), the Clinical Pharmacogenetics Implementation Committee (CPIC), and the Implementation of Genomics In pracTicE (IGNITE). As the Associate Director of Pharmacogenomics n the Hugh Kaul Personalized Medicine Institute, Dr. Limdi oversees discovery and clinical implementation of pharmacogenomics across the health UAB system. Through this initiative, her team has identified and overcome barriers, incorporated genotype-guided therapy and assessed clinically relevant outcomes to conduct economic analysis and inform health policy and reimbursement strategies for pharmacogenomics.
  • Selected Publications

    Research Overview

  • Harnessing the racial diversity of the population served at UAB, Dr. Limdi research and practice interests center around the evaluation of racial differences in the genetic underpinnings for drug response.
    1. Discovery of genetic variants and environmental factors influencing drug response
    2. Integrating clinical, genetic, socio-demographic and behavioral data to predict drug response
    3. Translating pharmacogenomic discoveries to health disparity populations
    4. Development of statistical genetic analysis approaches and methodologies
    5. Advancing Pharmacogenomics through collaborations with national and international consortia.
  • Principal Investigator On

  • Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population  awarded by National Human Genome Research Institute/NIH/DHHS 2020 - 2025
  • Predictors of Hemorrhage Among Patients on Direct Acting Oral Anticoagulants  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2020 - 2024
  • Patient Oriented Research in Personalized Antithrombotic Therapy  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2016 - 2021
  • Genetic and Clinical Predictors of Response to Warfarin and Novel Anticoagulants  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2014 - 2019
  • Collaborative Meta-Analysis of Genetic Predictors on Warfarin Response  awarded by UNIVERSITY OF VERONA 2017 - 2018
  • Pharmacogenomic Resource for Improving Medication Effectiveness (PRIME)  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION 2013 - 2017
  • Effect of Statins and Modifiable Factors on Stroke Outcome in Atrial Fibrillation  awarded by BOSTON MEDICAL CENTER 2010 - 2014
  • Racial Differences in Causes and Consequences of Medication Adherence  awarded by American Heart Association (Southeast Affiliate) 2014
  • Predictors of Thromboembolism and Hemorrhage in Patients on Ventricular Assist Devices  awarded by American Heart Association 2013 - 2014
  • Prediction of Warfarin Dosing Using Clinical and Genetic Factors  awarded by University of Pennsylvania 2012 - 2014
  • Clinical Site Participation in Clarification of Optimal Anticoagulation Through Genetics (COAG) Clinical Trial  awarded by University of Pennsylvania 2011 - 2014
  • Genetic and Environmental Determinants of Warfarin Response  awarded by National Heart, Lung, and Blood Institute/NIH/DHHS 2008 - 2014
  • The Student Scholarship in Cardiovascular Diseases  awarded by American Heart Association 2012 - 2013
  • Private Grant  awarded by DIAGNOSTICA STAGO, INC 2012 - 2013
  • Teaching Overview

  • In addition to research and implementation, Dr. Limdi is committed to developing talent through mentorship: She brings a comprehensive and diverse set of skills, and expertise in pharmacy practice, pharmacology, pharmacogenomics, clinical research methods, epidemiology and biostatistics to didactic teaching and training residents, post-doctoral trainees and junior faculty.
  • Education And Training

  • Doctor of Philosophy in Epidemiology, University of Alabama at Birmingham 2007
  • Master of Public Health, University of Alabama at Birmingham 2005
  • Doctor of Pharmacy, Samford University 1994
  • Bachelor of Pharmacy in Pharmacy, Pharmaceutical Sciences, and Administration, Samford University 1993
  • Bachelor of Pharmacy in Pharmacy, Pharmaceutical Sciences, and Administration, 1988
  • Full Name

  • Nita Limdi